We believe that the application of AEAC in glioma therapy may be effective due to its dual cytotoxic action: (1) disruption of GAPDH chaperoning, as indicated above, and (2) blocking of the antiapoptotic activity of Hsp70, as we showed earlier [18]. The gene discussed is HSPA1A; the disease is glioma.